Replies to post #226 on Contrafect Corp (CFRX)

[$5.95akadawson-m]

FDA approves Execabase this morning!

Stock up.

Whole market taking a beating because of Covid-19.



ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis